SEMINAR REPORT

ONCOLOGY: HEMATOLOGIC MALIGNANCIES OMI MEX MSKCC SEMINAR

October 9-11, 2023

Medical Education Beyond Borders

Memorial Sloan Kettering Cancer Center

© Open Medical Institute 2023
23 fellows from Mexico

16 fellows’ case presentations

4 faculty members from the USA and Mexico

2 excellent case presentations

12 didactic lectures

2 fellows’ case presentation sessions
<table>
<thead>
<tr>
<th>Time</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Monday October 9</td>
<td>Tuesday October 10</td>
<td>Wednesday October 11</td>
</tr>
<tr>
<td>08:00 – 09:00</td>
<td>REGISTRATION &amp; BREAKFAST</td>
<td>REGISTRATION &amp; BREAKFAST</td>
<td>REGISTRATION &amp; BREAKFAST</td>
</tr>
<tr>
<td>09:00 – 10:00</td>
<td>Introductions</td>
<td>Updates on MPN (MF, PV, ET)</td>
<td>Update on Treatment of Relapse and</td>
</tr>
<tr>
<td></td>
<td>Pre-Seminar Test</td>
<td>Raajit K. Rampal, MD, PhD</td>
<td>Refractory Myeloma</td>
</tr>
<tr>
<td>10:00 – 11:00</td>
<td>Updates in CML and Systemic Mastocytosis</td>
<td>Advances in Diffuse Large B-Cell Management</td>
<td>Transplant for Older Patients with</td>
</tr>
<tr>
<td></td>
<td>Raajit K. Rampal, MD, PhD</td>
<td>Gilles Salles, MD, PhD</td>
<td>Myeloid Leukemias</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>COFFEE BREAK</td>
<td>COFFEE BREAK</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>11:30 – 12:30</td>
<td>Updates on AML</td>
<td>Advances in Mantle Cell Management</td>
<td>What Can Be Done to Reduce Relapse and</td>
</tr>
<tr>
<td></td>
<td>Raajit K. Rampal, MD, PhD</td>
<td>Gilles Salles, MD, PhD</td>
<td>Toxicity after Transplant</td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>Updates on MDS</td>
<td>Advances in Hodgkin Lymphoma Management</td>
<td>Post-Seminar Test</td>
</tr>
<tr>
<td></td>
<td>Raajit K. Rampal, MD, PhD</td>
<td>Gilles Salles, MD, PhD</td>
<td>Evaluation &amp; Discussion</td>
</tr>
<tr>
<td>13:30 – 14:30</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CLOSING CEREMONY &amp; AWARDS</td>
</tr>
<tr>
<td>14:30 – 15:30</td>
<td>Advances in Follicular Lymphoma Management</td>
<td>Update on Upfront Therapy for Myeloma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilles Salles, MD, PhD</td>
<td>Sergio A. Giralt, MD</td>
<td></td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Workshop* Fellows’ Case Presentations</td>
<td>Workshop* Fellows’ Case Presentations</td>
<td></td>
</tr>
</tbody>
</table>
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center and the Open Medical Institute. Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement
Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Sergio A. Giralt, MD is a board-certified hematologist-oncologist with clinical activity and research focused on stem cell transplantation for patients with blood disorders. He trained and worked for many years at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020. Dr. Giralt’s research focus has been on improving treatments for older patients who have acute and chronic leukemia. He and his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers. Before this discovery, older patients with these diseases were rarely considered candidates for stem cell transplantation procedures using donor cells because of the toxic effects of high-dose chemotherapy. The development of these less intense and less toxic regimens has allowed transplants for older patients in a safe and effective manner and has changed the standard of care throughout the world. Dr. Giralt plans to continue research in the context of the pioneering T cell depletion techniques developed at Memorial Sloan Kettering. Dr. Giralt is an expert in the treatment of multiple myeloma, a blood cancer that affects plasma cells (the cells that produce the antibodies that protect us against infections). His research in this area has focused on developing new conditioning regimens for autologous transplant, a treatment approach in which patients receive an infusion of their own stem cells or bone marrow following a course of high-dose chemotherapy, as well as developing strategies that will reduce “symptom burden” and make the treatment so tolerable that it can be done on an outpatient basis. The goal is to deliver the most effective therapies with minimum symptom burden. Dr. Giralt led the Myeloma Intergroup Committee of the Blood and Marrow Clinical Trials Network, which developed the current national study looking at the role of consolidation therapy after autologous stem cell transplant for patients with myeloma. As a strong believer in collaborative science among large academic centers, he has been involved in many multi-institutional projects and until recently chaired the executive board of the Center for International Blood and Marrow Transplant Research. He is the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States.
Alvaro Aguayo González, MD

Medical Oncologist and Hemato-Oncologist
ABC Cancer Center
Head
Department of Oncology and Hematology
National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)
Mexico City
Email: alvaro.aguayog@incmnsz.mx

Alvaro Aguayo González, MD trained as a surgeon at the National Autonomous University of Mexico (UNAM) and later specialized in Internal Medicine and Hematology at the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ). In addition, he completed a specialty in Leukemia and Bone Marrow Transplantation, as well as residency in Medical Oncology at the MD Anderson Cancer Center in Houston, Texas. He obtained the certificate of the Educational Commission of Foreign Medical Graduates (ECFMG) and the United States Medical Licensing Examination (USMLE). He is an expert in Leukemia, Lymphomas, Multiple Myeloma, Breast Cancer, Colon Cancer, and Pancreatic Cancer. In 1999, he was awarded the MD Anderson Cancer Center with the Clinical Fellow Research Award. In 2007, 2021, and 2022 he received the award for the best professor of clinical sciences from the School of Medicine of the Universidad Panamericana. Currently, he is Head of the Department of Oncology and Hematology at INCMNSZ, Medical Oncologist and Hemato-Oncologist at the Hospital ABC Cancer Center, and National Researcher Level 1 of the National System of Researchers of CONACYT. He is a Full Member of the National Academy of Medicine and the past President of the Society of Chemo-Radiotherapy of the ABC Cancer Center. He has participated in multiple conferences in Hematology and Oncology in the United States, Canada, Europe, and Latin America. He is Professor of Hematology at the Universidad Panamericana (UP) and Adjunct Professor of the Postgraduate Course at UNAM. He is a member of the INCMNSZ research ethics committee and is part of several medical associations in Mexico and the United States.
Raajit K. Rampal, MD, PhD

Associate Attending Physician
Clinical Director, Leukemia Service
Director, MPN and Rare Hematologic Malignancies Program
Memorial Sloan Kettering Cancer Center
530 East 74th street
New York, NY 10021
USA
Email: rampalr@mskcc.org

Raajit K. Rampal, MD, PhD is Associate Attending Physician and Director of the MPN and Rare Hematologic Malignancies Program at Memorial Sloan-Kettering Cancer. He received his undergraduate degree in Biochemistry from the University of Rochester. He subsequently went on to train in the Medical Scientist Training Program (MSTP) at Stony Brook University. This was followed by internship and residency at the University of Chicago, as part of the Physician-Scientist Development Program. Dr. Rampal then went on to fellowship in hematology and medical oncology at Memorial Sloan-Kettering Cancer Center. The focus of his research has been to elucidate mechanism of pathogenesis in the Myeloproliferative Neoplasms (MPN) and secondary AML, as well as to investigate novel therapeutic approaches in myeloid malignancies. His clinic focuses on the care of patients with MPNs, MDS, and AML.
Gilles Salles, MD, PhD

Chief
Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weil Cornell Medical College
530 East 74th street
New York, NY 10021
USA

Email: SallesG@mskcc.org

Gilles Salles, MD, PhD is the Chief of the Lymphoma Service and Steven Greenberg Chair at the Memorial Sloan Kettering Cancer Center in New York, as well as Professor of Medicine at Weil Cornell Medical College. He has previously held a position of professor of hematology and medicine at the University of Lyon, and head of the Department of Hematology at the Centre Hospitalier Lyon-Sud, in Pierre-Bénite, France. Dr. Salles obtained his doctoral degree in differentiation, genetics, and immunology, as well as his medical degree, from Université Claude Bernard Lyon-1. He completed further training in Oncology and also served as a researcher at the Dana-Farber Cancer Institute of Harvard Medical School in Boston, Massachusetts, USA. During his career, Dr. Salles has been especially interested in the clinical and biological study of Lymphoma. The primary focus of his work is on the description and validation of prognostic factors and clinical trials in indolent Lymphomas. He also examined several aspects of Lymphoma biology including T- and B-cell Lymphoma models, signaling, genomic biology of indolent Lymphomas, and prognostic factors with his team. Dr. Salles has been involved in the investigation and development of new therapeutic agents, such as several targeted therapies, new monoclonal antibodies and other immunotherapies in the field. He led large international studies evaluating treatment options in patients with follicular lymphoma. Previously, Dr. Salles chaired the Lymphoma Study Association, a European cooperative group. He is also a member of several international societies, including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Salles is the author of more than 500 publications, including articles in international peer-reviewed journals such as The New England Journal of Medicine, Blood, Journal of Clinical Oncology, The Lancet, Haematologica, Lancet Oncology, and Leukemia and Lymphoma.
Becky Aguilar-Álvarez de Sáenz
Executive Director | AMSA

• Bachelors degree in economics, Instituto Tecnológico Autónomo de México (ITAM)
• Banking and financial career for 15 years
• Member of the Board Civic Committee, Ford Motor Company Mexico
• Treasurer of the Board of Trustees UNETE (Unión de Empresarios por la Tecnología en la Educación)
• Member of the International Women’s Forum
• Member of the Mexican Council for International Affairs
• AMSA’s Executive Director since 2010

Gerardo Legorreta Creel
Chairman | AMSA

• Chairman of the Board of Trustees, Alianza Médica para la Salud, A. C. (AMSA)
• Studied at the London Business School and Instituto Tecnológico Autónomo de México (ITAM)
• CEO of UBS (Union Bank of Switzerland)
• Member of the Board of Directors of Bepensa, SA de CV
• Founder and Managing Director of LG & A
FELLOWS

Fior Maria Armillas, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Department of Hematology
Vasco de Quiroga 15 Sección XVI
14000 Mexico City
Mexico
fmarmillas@gmail.com

Irlanda Campos, MD
Instituto Nacional de Pediatria
Department of Hematology
Insurgentes Sur 3700
04530 Mexico City
Mexico
irlanda.1703@gmail.com

Rodely Angelica De Leon Cruz, MD
Instituto Nacional de Pediatria
Department of Pediatrics
Iman Avenue
04530 Mexico City
Mexico
rodelydlc@gmail.com

Marcela Deffis-Court, MD
Hospital Médica Sur
Department of Hematology
Puente de Piedra 150 Toriello Guerra Tlapian
14050 Mexico City
Mexico
mdeffis@hotmail.com

Luisa Duarte, MD
Instituto Nacional de Pediatria
Department of Pediatrics
Insurgentes Sur
04530 Mexico City
Mexico
luisaduar.ar@gmail.com
Veronica Esquivel Lujano, MD
HGR251
Department of Oncology
Arbol de la Vida 501 Bosques de Metepec
52148 Metepec
Mexico
veronicaesquivel@live.com.mx

Elizabeth Araceli Estrada Gomez, MD
Hospital de Pediatria Centro Medico Nacional
Siglo XXI Instituto Mexicano del Seguro Social
Department of Oncology
Av. Cuauhtemoc #330
06720 Mexico City
Mexico
onco.eliesgo@gmail.com

Omar Eduardo Fernandez Vargas, MD, MSc
Instituto Nacional de Cancerologia
Department of Hematology
Avenida San Fernando 22
14080 Mexico City
Mexico
ofernandezvargas@icloud.com

Marilyn Viridiana Flores Mendoza, Dr. habil.
Department of Hematology
Insurgentes Cuiculco
04530 Villahermosa, Tabasco
Mexico
marilyn_0418@hotmail.com

Gabriela Alicia Hernández Echáurregui, MD
Department of Oncology
Calle Oriente 158
15530 Mexico City
Mexico
gher8601@hotmail.com

Andrea Priscila Hernandez Perez, MD
Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran
Vasco de Quiroga
14080 Mexico City
Mexico
anddez.mc@gmail.com
Sergio Rodriguez Rodriguez, MD, MSc
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Department of Hematology
Av. Vasco de Quiroga 15
14080 Mexico City
Mexico
sergio.rodriguez.rodriguez@gmail.com

Luis Felipe Rubalcava, MD
Instituto Nacional de Cancerología - México
Department of Hematology
Avenida San Fernando
14080 Mexico City
Mexico
rubalcava_luisfelipe@hotmail.com

Daniela Sánchez Martínez, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Department of Hematology
Vasco de Quiroga 15, Belisario Domínguez
14080 Mexico City
Mexico
danysm.sam@gmail.com

Fernando Solís-Huerta, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Department of Hematology
Avenida Vasco de Quiroga #15
14080 Mexico City
Mexico
ferna.der.hem@outlook.com

Diana Laura Tavira Carbajal, MD
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Department of Hematology
Vasco de Quiroga
14080 Mexico City
Mexico
diana.tavirac@gmail.com

Gonzalo Vancini Becerra, BSc
Instituto Mexicano del Seguro Social
Department of Hematology
Blvd. Manuel Ávila Camacho s/n
54050 Mexico State
Mexico
gonzv40@gmail.com
"The OMI MEX Oncology: Hematologic Malignancies seminar was an extraordinary, well organized meeting. The fellows were engaged, inquisitive, and had wonderful questions. The cases were well presented and highlighted the challenges they have in their daily practices. More importantly, the fellows not only left with up-to-date knowledge, but also with the desire to develop strategies that could improve local outcomes with available resources."

Sergio A. Giralt, MD
Oncology: Hematologic Malignancies

Memorial Sloan Kettering Cancer Center
OMI VOICES

"After my case presentation, I received great feedback in patient management and care. All the cases raised clinical doubts, but the discussion and interaction helped us solve different clinical enigmas that may affect all the hematologists who were present at the seminar."

Sergio Rodriguez-Rodriguez, M.D.
OMI MEX Fellow from Mexico

"Dr. Salles and I discussed my questions during the coffee break. It was awesome to be part of this dynamic, in which top notch physicians with so much experience interacted with us so naturally."

Aldo Aguirre Landeras Perez, M.D.
OMI MEX Fellow from Mexico

"The opportunity to learn about follicular lymphoma and diffuse large B-cell lymphoma, as well as updates on new treatment approaches, was especially informative and interesting for me. The expert faculty were excellent presenters and conveyed their knowledge to us in the best way possible."

Diana Loura Trejo Carabap, M.D.
OMI MEX Fellow from Mexico
CONTACT

Salzburg Stiftung der AAF
Schloss Arenberg
Arenbergstrasse 10
5020 Salzburg | Austria

+43 662 640 101

seminars@openmedicalinstitute.org

www.openmedicalinstitute.org

www.openmedicalinstitute.org/news

portal.openmedicalinstitute.org
Follow us

Open Medical Institute
Now on Instagram

@openmedicalinstitute